| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.101.7.751 |
| P698 | PubMed publication ID | 10683348 |
| P50 | author | A Michael Lincoff | Q63038136 |
| Robert Califf | Q19281782 | ||
| Eric J. Topol | Q5387640 | ||
| P2093 | author name string | K S Pieper | |
| M L Simoons | |||
| R A Harrington | |||
| N S Kleiman | |||
| E Boersma | |||
| D V Cokkinos | |||
| R G Wilcox | |||
| L G Berdan | |||
| G C Flaker | |||
| T J Lorenz | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 751-757 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators | |
| P478 | volume | 101 |
| Q34111637 | A critical appraisal of platelet glycoprotein IIb/IIIa inhibition |
| Q44372469 | Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates |
| Q37929839 | Anti-platelet therapy: glycoprotein IIb-IIIa antagonists |
| Q38075455 | Antiplatelet medications and evolving antithrombotic medication |
| Q26830199 | Clinical and economic studies of eptifibatide in coronary stenting |
| Q28188309 | Clopidogrel in invasive management of non-ST-elevation ACS |
| Q34093139 | Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study |
| Q52682156 | Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. |
| Q28200685 | Current developments in anti-platelet therapy |
| Q24792327 | Debate: Unstable angina - When should we intervene? |
| Q44041809 | Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina |
| Q28185738 | Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial |
| Q44621238 | Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST–elevation myocardial infarction (PRISM-PLUS study) |
| Q54937991 | Eptifibatide Bolus Dose During Elective Percutaneous Coronary Intervention. |
| Q33391279 | Eptifibatide: The evidence for its role in the management of acute coronary syndromes |
| Q28198893 | Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes |
| Q81214093 | Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention |
| Q40987162 | Immediate outcomes of eptifibatide therapy during intracoronary stent implantation |
| Q47820176 | Insurance status and the treatment of myocardial infarction at academic centers |
| Q41470605 | Intravenous hemostat: nanotechnology to halt bleeding. |
| Q34727611 | Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance |
| Q44158698 | Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study |
| Q34053362 | Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial. |
| Q28219726 | Myocardial infarct and unstable angina pectoris: diagnostics and therapy |
| Q36085620 | Newer agents in antiplatelet therapy: a review |
| Q44541860 | Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile |
| Q34336824 | Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: initiate treatment early or wait for the catheterization laboratory? |
| Q37424804 | Sex differences in mortality following acute coronary syndromes |
| Q45877421 | Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods. |
| Q36817207 | The NVVC working group guidelines for the management of patients with non-ST-elevation acute coronary syndromes |
| Q33333976 | The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease |
| Q34661939 | Volatile anesthetics, not intravenous anesthetic propofol bind to and attenuate the activation of platelet receptor integrin αIIbβ3. |
Search more.